Optimising nanoparticles: harnessing quality by design through 3-level factorial design and box-behnken methodology

Saravanan R

doi:10.47957/ijpda.v12i3.600

Authors

R Saravanan Head of Department , Faculty of Pharmacy , Bharath Institute of Higher Education and Research , Chennai 600073 , India

DOI:

https://doi.org/10.47957/ijpda.v12i3.600

Keywords:

Nanoparticles, Quality by Design (QbD)

Abstract

Nanoparticles (NPs) have become essential elements in a number of scientific and industrial domains, such as materials research, drug delivery, and diagnostics, because of their special qualities and potential for focused uses. An ideal formulation procedure is essential to maximising the effectiveness and efficiency of nanoparticles. In order to optimise the formulation and production processes for nanoparticles, this research investigates the application of Quality by Design (QbD) principles in conjunction with sophisticated statistical approaches, namely the 3-level factorial design and the Box-Behnken methodology. The Quality by Design methodology is a methodical approach that prioritises predetermined goals, in-depth process comprehension, and careful control grounded in reliable science and quality risk management. When QbD is incorporated into nanoparticle optimisation, reliable and repeatable formulations that adhere to specifications with little variation are guaranteed. To look into how different factors interact and affect the properties of nanoparticles, the 3-level factorial design is used. With this design approach, a thorough understanding of the process variables can be obtained by exploring a broad variety of component values. Critical quality attributes (CQAs) include important parameters such drug encapsulation efficiency, zeta potential, polydispersity index (PDI), and particle size. These parameters are methodically examined to determine the ideal amounts of each. To further refine the 3-level factorial design, the Box-Behnken methodology is applied. Without the requirement for extensive combination testing, this response surface methodology (RSM) is especially useful for building second-order polynomial models and investigating quadratic response surfaces. By enabling a more accurate comprehension of the interactions between inputs and responses, the Box-Behnken design improves the optimisation process and makes it easier to identify the ideal circumstances for nanoparticle synthesis. By utilising both approaches in tandem, this work methodically determines ideal formulation parameters that minimise nanoparticle size and polydispersity while optimising stability and drug loading efficiency. The outcomes highlight how important a QbD framework is for directing the creation of reliable nanoparticle systems that function consistently and predictably.

Downloads

Download data is not yet available.

References

Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20. https://pubs.acs.org/doi/10.1021/nn900002m.

Jain KK. The role of nanotechnology in drug discovery. Drug Discov Today. 2005;10(21):1435-1442. https://pubmed.ncbi.nlm.nih.gov/16243263/

Rapalli VK, Banerjee S, Khan S, Jha PN, Gupta G, Dua K, Hasnain MS, Nayak AK, Dubey SK, Singhvi G. QbD-driven formulation development and evaluation of topical hydrogel containing ketoconazole loaded cubosomes. Mater Sci Eng C. 2021;119:111548.https://doi.org/10.1016/j.msec.2020.111548

Lobatto ME, Fuster V, Fayad ZA, Mulder WJ (2011) Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 10(11):835–852. https://doi.org/10.1038/nrd3578

Saleem H, Zaidi SJ. Developments in the application of nanomaterials for water treatment and their impact on the environment. Nanomaterials. 2020;10(9):1764. https://doi.org/10.3390/nano10091764

McNeil SE. Nanotechnology for the biologist. J Leukoc Biol. 2005;78(3):585-594. https://doi.org/10.1189/jlb.0205074Journal

Beg S, Swain S, Singh SB, Patra CN. Development, optimization, and characterization of solid lipid nanoparticles of an antiretroviral drug using response surface methodology. Chem Eng Res Des. 2012;90(3):421-431. https://doi.org/10.1016/j.cherd.2011.08.006

Nagarajan R, Hatton TA. Nanoparticles: Synthesis, Stabilization, Passivation, and Functionalization. ACS Symposium Series 996. 2008. https://pubs.acs.org/doi/book/10.1021/bk-2008-0996

Moura LG, Nóbrega FP, Diniz LS, Diniz R, Pacheco WF, Diniz MM. Optimization of polymeric nanoparticles loaded with amphotericin B using a 32 full factorial design. J Biomed Nanotechnol. 2014;10(3):404-412. https://doi.org/10.1166/jbn.2014.1691

Shah B, Misra A. Studies on aceclofenac-loaded PLGA nanoparticles: In vitro and in vivo evaluation. J Biomed Nanotechnol. 2014;10(3):399-407. https://doi.org/10.1166/jbn.2014.1690

Kushwaha AK, Vuddanda PR. Development and optimization of nevirapine-loaded PLGA nanoparticles: in vitro and in vivo studies. J Drug Deliv Sci Technol. 2018;43:293-302. https://doi.org/10.1016/j.jddst.2017.10.022

L.X. Yu, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771-83.https://link.springer.com/article/10.1208/s12248-014-9598-3

Rapalli VK, Khosa A, Singhvi G, Girdhar V, Jain R, Dubey SK. Application of QbD Principles in Nanocarrier-Based Drug Delivery Systems. In: Pharmaceutical Quality by Design: Principles and Applications. 2019. p. 255-96. https://doi.org/10.1016/B978-0-12-815799-2.00014-9

Rapalli VK, Singhvi G, Dubey SK, Gupta G, Chellappan DK, Dua K. Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed Pharmacother. 2018;106:707-13.https://doi.org/10.1016/j.biopha.2018.06.136

Patel H, Parmar S, Patel B. A Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals. Int J Pharm Sci Rev Res. 2013;21(1):223-36. www.globalresearchonline.net

Lionberger RA, Lee SL, Lee L, et al. Quality by Design: Concepts for ANDAs. AAPS J. 2008;10:268-76 https://doi.org/10.1208/s12248-008-9026-7

Sethuramiah A, Kumar R. Statistics and Experimental Design in Perspective. In: Modeling of Chemical Wear: Relevance to Practice. 2016. p. 129-59.https://doi.org/10.1016/B978-0-12-804533-6.00006-8

Thapa P, Tripathi J, Jeong SH. Recent trends and future perspective of pharmaceutical wet granulation for better process understanding and product development. Powder Technol. 2019;344:864-82.https://doi.org/10.1016/j.powtec.2018.12.080

Beg S, Rahman M, Jain A. Quality-by-design approach for the development and optimization of nanomaterials. Crit Rev Ther Drug Carrier Syst. 2017;34(3):219-48.https://doi.org/10.1016/B978-0-12-821095-6.00006-9

Kumar S, Bhanjana G. Quality by design (QbD) in pharmaceuticals: a comprehensive review. Int J Pharm Sci Rev Res. 2014;25(2):20-5. https://ijprajournal.com/issue_dcp/Quality%20by%20Design%20(QbD)%20A%20Comprehensive%20Review..pdf

Nasr MM. Quality by design (QbD) in the pharmaceutical industry: Status and future perspectives. Pharm Dev Technol. 2010;15(2):91-102. https://doi.org/10.3390/pharmaceutics12050409

Deng Y, Zhang X, Shen H, He Q, Wu Z, Liao W, Yuan M. Application of the nano-drug delivery system in treatment of cardiovascular diseases. Front Bioeng Biotechnol. 2020;7:489 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005934/

Badawy AM, Hussain MA. Quality by design (QbD) in pharmaceutical manufacturing: from development to market. Pharm Eng. 2013;33(4):48-60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070262/

Singh B, Chakkal SK. Quality by design (QbD) in the development of nanoparticles-based formulations. Nanomedicine. 2014;10(4):465-78. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465123/

Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781-91. https://link.springer.com/article/10.1007/s11095-007-9511-1

ICH Harmonised Tripartite Guideline Q8 (R2). Pharmaceutical Development. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2009.https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf

Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics. 1960;2(4):455-75.https://www.jstor.org/stable/1266454

Trivedi D, Spandana A, Kuppusamy G, Kar VVS. Design of Experiments: Optimization and Applications in Pharmaceutical Nanotechnology. March 2015;2015(4(13)):109-20 https://www.researchgate.net/publication/281202382_Design_of_Experiments_Optimization_and_Applications_in_Pharmaceutical_Nanotechnology

Chen C, Xu Y. Application of Box-Behnken design in the optimization of nanomaterial properties. J Nanoscience Nanotechnol. 2015;15(10):7723-30.https://doi.org/10.3109/10837450902882385

Pillai O, Sawant KK. Nanoparticle formulations for oral delivery: A review. Int J Pharm. 2013;453(1-2):1-9. doi: 10.1016/j.ijpharm.2013.06.053. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122152/

Barabadi H, Honary S, Ebrahimi P, Alizadeh A, Naghibi F, Saravanan M. Optimization of myco-synthesized silver nanoparticles by response surface methodology employing Box-Behnken design. Inorg Nano-Metal Chem. 2019;49(2):33-43.https://doi.org/10.1080/24701556.2019.1583251

Elmizadeh H, Khanmohammadi M, Ghasemi K, Hassanzadeh G, Nassiri-Asl M, Bagheri Garmarudi A. Preparation and optimization of chitosan nanoparticles and magnetic chitosan nanoparticles as delivery systems using Box–Behnken statistical design. J Pharm Biomed Anal. 2013;80:141-6.https://doi.org/10.1016/j.jpba.2013.02.038

Tripathi MG, Yadav PB, Agrawal VK, Ghosh RK, Patel SK. Optimization of chitosan nanoparticles for controlled delivery of antidiabetic drugs: Development and in vitro characterization. J Pharm Res. 2013;7(6):865-72. doi: 10.1016/j.jopr.2013.05.022.https://doi.org/10.1016/j.jopr.2013.05.022

Olsson TM, Anderson HA, McCarthy SF, et al. Advances in the development of metal-organic frameworks for energy storage and conversion applications. Mater Sci Eng C. 2019;98:784-97.https://doi.org/10.1016/j.msec.2019.02.06

Jamrogiewicz M. Application of the near-infrared spectroscopy in the pharmaceutical technology. J Pharm Biomed Anal. 2012;66:1–10https://pubmed.ncbi.nlm.nih.gov/21167266/

Islam M.T., Maniruzzaman M., Halsey S.A. Development of sustained-release formulations processed by hot-melt extrusion by using a quality-by-design approach. Drug Deliv Transl Res. 2014;4(4):377–387 https://pubmed.ncbi.nlm.nih.gov/25787069/

Wu H., White M., Khan M.A. Quality-by-Design (QbD): an integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. Int J Pharm. 2011;405(1–2):63–78 https://pubmed.ncbi.nlm.nih.gov/21138762/

Orlandini S., Pinzauti S., Furlanetto S. Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem. 2013;405(2–3):443–450.https://pubmed.ncbi.nlm.nih.gov/22941176/

Corredor C.C., Lozano R., Bu X. Analytical method quality by design for an on-line near-infrared method to monitor blend potency and uniformity. J Pharm Innov. 2015;10(1):47–55.https://scholar.google.com/scholar_lookup?journal=J+Pharm+Innov&title=Analytical+method+quality+by+design+for+an+on-line+near-infrared+method+to+monitor+blend+potency+and+uniformity&author=C.C.+Corredor&author=R.+Lozano&author=X.+Bu&volume=10&issue=1&publication_year=2015&pages=47-55&

Patwardhan K., Asgarzadeh F., Dassinger T. A quality by design approach to understand formulation and process variability in pharmaceutical melt extrusion processes. J Pharm Pharmacol. 2015;67(5):673–684.https://pubmed.ncbi.nlm.nih.gov/25615235/

Cunha S, Costa CP, Moreira JN, Lobo JS, Silva AC. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review. Nanomed Nanotechnol. 2020;28:102206. https://doi.org/10.1016/j.nano.2020.102206.

Swain, S.; Parhi, R.; Jena, B.R.; Babu, S.M. Quality by design: concept to applications. Curr. Drug Discov. Technol. 2019, 16, 240-250, https://dx.doi.org/10.2174/1570163815666180308142016.

Mishra, V.; Thakur, S.; Patil, A.; Shukla, A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin. Drug Deliv. 2018, 15, 737-758, https://doi.org/10.1080/17425247.2018.1504768.

Kenett, R.S.; Kenett, D.A. Quality by design applications in biosimilar pharmaceutical products. Accreditation Qual. Assur. 2008, 13, 681-690, http://dx.doi.org/10.1007/s00769-008-0459-6.

Politis, S.N; Colombo, P.; Colombo, G.; Rekkas, D.M. Design of experiments (DoE) in pharmaceutical development. Drug Dev. Ind. Pharm. 2017, 43, 889-901, http://dx.doi.org/10.1080/03639045.2017.1291672.